PROCÉDÉS DE CRIBLAGE POUR IDENTIFIER ET TRAITER DES SOUS-POPULATIONS DE PATIENTS INFECTÉS PAR LE VIH-1 APPROPRIÉS POUR UNE THÉRAPIE À LONG TERME AVEC UN AGENT ANTI-CCR5

摘要

Certain R5 virus tropic HIV-1 subjects with viral load effectively conventionally controlled using HAART, i.e., subject having less than 50 viral copies/mL (<50 cp/mL), may be substantially more susceptible than others to effective monotherapy treatment using anti-CCR5 agents, e.g, PRO 140 mAbs. Certain HIV-1 subjects using PRO 140 monotherapy treatment may experience prolonged or unlimited time periods with actual undetectable viral loads, extremely low viral load counts ≤ 1 cp/mL, very low, or low levels, or at conventionally undetectable levels, during monotherapy. Increasing dose amounts of anti-CCR5 agents, e.g., PRO 140, from 350 mg to 525 mg or 700 mg, may beneficially suppress a subject's viral load count before, during, and/or maintain effective prolonged monotherapy and may shorten the period of time necessary to determine if a subject will respond positively to PRO 140 monotherapy to less than eight (8) weeks. This invention includes protocols, methods, and kits.